Acute Equol Supplementation and Vascular Function in Women With and Without CKD
NCT06128278
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Kidney Diseases
- Vascular Function
- Women
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 50 to 69 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- September 30, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Anschutz Medical Campus · Aurora, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.